Novel polymerase chain reaction approach for full-coding p53 mutation detection in microdissected archival tumors

Diagnostic Molecular Pathology

Volumn 9, Issue 2, 2000, Pages 110-119

  Thompson Hehir, Jo ^a   Davies, Michael P A ^c   Green, John A ^c   Halliwell, Nigel ^c   Joyce, Kathryn A ^c   Salisbury, Jean ^c   Sibson, D Ross ^c   Vergote, Ignace ^b   Walker, Carol ^c  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c NONE

Author keywords

Archival sample; Mutation detection; Ovarian cancer; p53; Polymerase chain reaction; Tumor

Indexed keywords

PROTEIN P53;

AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ARTICLE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; GENE INSERTION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; INTRON; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SPLICING;

BASE SEQUENCE; CARCINOMA; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; DNA, NEOPLASM; ELECTROPHORESIS, AGAR GEL; FEMALE; HUMANS; MALE; MICROMANIPULATION; MOLECULAR SEQUENCE DATA; MUTATION; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034091498     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019606-200006000-00007     Document Type: Article

References (57)

1. Angelopoulou K, Diamandis EP. Identification of deletions and insertions in the p53 gene using multiplex PCR and high resolution fragment analysis: Application to breast and ovarian tumors. J Clin Lab Anal 1998;12:250-6.
2. Angelopoulou K, Levesque MA, Katsaros D, Shipman R, Diamandis EP. Exon 5 of the p53 gene is a target for deletions in ovarian cancer. Clin Chem 1998;44:72-7.
3. Austoker J. Screening for ovarian, prostatic, and testicular cancers. BMJ 1994;309:315-20.
4. Berthon P, Dimitrov T, Stower M, Cussenot O, Maitland NJ. A microdissection approach to detect molecular markers during progression of prostate cancer. BJC 1995;72:946-51.
5. Bharaj BS, Angelopoulou K, Diamandis EP. Rapid sequencing of the p53 gene with a new automated DNA sequencer. Clin Chem 1998;44:1397-403.
6. Bohm M, Wieland I. Analysis of tumor-specific alterations in native specimens by PCR: How to procure the tumor cells. Int J Oncol 1997;10:131-9.
7. Buller RE, Sood A, Fullenkamp C, Sorosky J, Powills K, Anderson B. The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther 1997;4:239-45.
8. Buttitta F, Marchetti A, Gadduchi A, et al. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997;75:230-5.
9. Chen T, Dhingra K, Sahin A, Sneige N, Hortobagyi G, Marcelo Aldaz C. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. Breast Cancer Res Treat 1996;39:177-85.
10. Cheung VA, Nelson SF. Whole genome amplification using a degenerate oligonucleotide primer allows hundreds of genotypes to be performed on less than one nanogram of genomic DNA. Proc Natl Acad Sci 1996;93:14676-9.
11. Cottu PH, Muzeau F, Estreicher A, Flejou JF, Iggo R, Thomas G, Hamelin R. Inverse correlation between RER(+) status and p53 mutation in colorectal cancer cell lines. Oncogene 1996;13:2727-30.
12. Coukos G, Rubin SC. Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstet Gynecol 1998;91:783-91.
13. Davies MPA, Gibbs FEM, Halliwell N, et al. Mutation in the PTEN /MMAC1 gene in archival low grade and high grade gliomas. Br J Cancer 1999;79:1542-8.
14. Easty DM, Easty GC, Carter RL, Monaghan P, Botler LJ. Ten human carcinoma cell-lines derived from squamous carcinomas of the head and neck. Br J Cancer 1981;43:172-84.
15. El-Deiry WS. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9:79-87.
16. Frank TS, Bartos RE, Haefner HK, Roberts JA, Wilson MD, Hubbell GP. Loss of heterozygosity and overexpression of the p53 gene in ovarian cancer. Mod Pathol 1994;7:3-8.
17. Gibbs et al. manuscript in preparation.
18. Going JJ, Lamb RF. Practical histological microdissection for PCR analysis. J Pathol 1996;179:121-4.
19. Gusterson BA, Anbazhagan R, Warren W, et al. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene 1991;6:1785-9.
20. Hall PA, Lane DP. p53 in tumor pathology - can we trust immunohistochemistry - revisited. J Pathol 1994;172:1-4.
21. Hartmann A, Blaszyk H, McGovern RM, et al. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene 1995;10:681-8.
22. Hedrum A, Ponten F, Ren Z, Lundberg J, Ponten J, Uhlen M. Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. Biotechniques 1994;17:118-29.
23. Henegariu O, Heerema NA, Dlouhy SR, Vance GH, Vogt PH. Multiplex PCR: Critical parameters and -step-by step control. Biotechniques 1997;23:504-11.
24. Herod JJO, Eliopoulus AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostics significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996;56:2178-84.
25. Kastrinakis WV, Ramchurren N, Rieger KM, Hess DT, Loda M, Steele G, Summerhayes IC. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression. Oncogene 1995;11:647-52.
26. Ko KJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10: 1054-72.
27. Kristensen GB, Trope C. Epithelial ovarian cancer. Br J Cancer 1997 349:113-7.
28. Kupryjanczykk J, Thor AD, Beauchamp R, Merritt V, Edgerton SM, Bell DA, Yandell DW. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-5.
29. Lin J, Chen J, Elenbaas B, Levine AJ. Several hydrophobic amino-acids in the p53 amino-terminal domain are required for transitional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev 1994;8:1235-46.
30. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
31. McManus DT, Yap EP, Maxwell P, Russell SE, Toner PG, McGee JO. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994;174:159-68.
32. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996;12:1617-23.
33. Murphy M, McManus DT, Toner PG, Russell SHE. TP52 mutation in ovarian carcinoma. Eur J Cancer 1997;33:1281-3.
34. Nollau P, Wagener C. Methods for detection of point mutations: performance and quality assessment. Clin Chem 1997;43:1114-28.
35. Ozols RF, Rubin SC, Thomas G, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia: Lippincott-Raven, 1997:919-87.
36. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V. Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep 1999;6:193-7.
37. Peller S, Yona R, Kopilova Y, et al. Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia. Genes Chromosomes Cancer 1998;21:2-7.
38. Perez RP, Hamilton TC, Ozols RF, Young RC. Mechanisms and modulation of resistance to chemotherapy in ovarian cancer. Cancer 1993:71:1571-80.
39. Righetti SC, Torre GD, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689-93.
40. Rines RD, van Orsouw NJ, Sigalas I, Li FP, Eng C, Vijg J. Comprehensive mutational scanning of the p53 coding region by two-dimensional gene scanning. Carcinogenesis 1998;19:979-84.
41. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV, Lane DP. p53 mutations in colorectal cancer. Proc Natl Acad Sci 1991;87:7555-9.
42. Sarkar FH, Kupsky WJ, Li Y-W, Sreepathi P. Analysis of p53 gene mutations in human gliomas by polymerase chain reaction-based single-strand conformation polymorphisms and DNA sequencing. Diagn Mol Pathol 1994;3:2-8.
43. Save V, Nylander K, and Hall PA. Why is p53 protein stabilised in neoplasia ? Some answers but many more questions ! J Pathol 1998;184:348-50.
44. Shelling AN. Role of p53 in drug resistance in ovarian cancer. Lancet 1997;349:744-5.
45. Shuber AP, Grondin VJ, and Klinger KW. A simplified procedure for developing multiplex PCRs. Genome Res 1995;5:488-93.
46. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet 1998;14:272-6.
47. Skilling JS, Squartrito RC, Connor JP, Niemann T, Buller RE. p53 gene mutation analysis and anti-sense mediated growth inhibition of human ovarian carcinoma cell lines. Gynecol Oncol 1996;60: 72-80.
48. Somers KD, Merrick MA, Lopez ME, Incognito LS, Schechter GL, Casey G, Frequent p53 mutations in head and neck cancer. Cancer Res 1992;52:5997-6000.
49. Soong R, Iacopette BJ. A rapid and nonisotopic method for the screening and sequencing of p53 gene mutations in formalin-fixed, paraffin-embedded tumors. Mod Pathol 1997;10:252-8.
50. Stewart LA, Guthrie D, Parmar MK, Williams CJ. Chemotherapy in advanced ovarian cancer. Br Med J 1992;304:119.
51. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papilloma virus-associated cancer. Nature 1998;393:229-34.
52. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demers GW, Galloway DA. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
53. Wang-Gohrke S, Hees S, Pochon A. Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples. Oncol Rep 1998;5:65-8.
54. Welsh JA, Castren K, Vahakangas KH. Single-strand conformation polymorphism analysis to detect p53 mutations: characterisation and development of controls. Clin Chem 1997;43:2251-5.
55. Wright-Perkins S, Daniel MR, Walker C. Characteristics of two cell-lines derived from a histologically undifferentiated bronchial carcinoma expressing neuroendocrine markers. In Vitro Cell Dev Biol Anim 1994;30A:450-9.
56. Yaginuma Y, Westphal H. Analysis of the p53 gene in human uterine carcinoma cell-lines. Cancer Res 1991;51:6506-9.
57. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-9.